Have a feature idea you'd love to see implemented?
Let us know!
AGIO Agios Pharmaceuticals Inc
Price (delayed)
$55.54
Market cap
$3.17B
P/E Ratio
4.71
Dividend/share
N/A
EPS
$11.79
Enterprise value
$2.97B
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In
Highlights
Agios Pharmaceuticals's equity has surged by 146% QoQ and by 83% YoY
Agios Pharmaceuticals's gross profit has increased by 38% YoY and by 5% QoQ
The quick ratio is down by 24% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of AGIO
Market
Valuations
Earnings
Shares outstanding
57.03M
Market cap
$3.17B
Enterprise value
$2.97B
Price to earnings (P/E)
4.71
Price to book (P/B)
1.94
Price to sales (P/S)
96.21
EV/EBIT
4.09
EV/EBITDA
4
EV/Sales
90.49
Revenue
$32.87M
EBIT
$727.43M
EBITDA
$744.44M
Free cash flow
-$330.07M
Per share
Balance sheet
Liquidity
EPS
$11.79
Free cash flow per share
-$5.8
Book value per share
$28.59
Revenue per share
$0.58
TBVPS
$31.47
Total assets
$1.79B
Total liabilities
$165.12M
Debt
$60.83M
Equity
$1.63B
Working capital
$954.74M
Debt to equity
0.04
Current ratio
8.99
Quick ratio
8.44
Net debt/EBITDA
-0.26
Margins
Efficiency
Dividend
EBITDA margin
2,264.7%
Gross margin
89.4%
Net margin
2,051.4%
Operating margin
1,466.8%
Return on assets
62%
Return on equity
70.2%
Return on invested capital
77.2%
Return on capital employed
43.5%
Return on sales
2,213%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AGIO stock price
How has the Agios Pharmaceuticals stock price performed over time
Intraday
1.68%
1 week
0.25%
1 month
21.64%
1 year
153.96%
YTD
149.39%
QTD
25.01%
Financial performance
How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$32.87M
Gross profit
$29.38M
Operating income
$482.16M
Net income
$674.31M
Gross margin
89.4%
Net margin
2,051.4%
Agios Pharmaceuticals's gross profit has increased by 38% YoY and by 5% QoQ
The revenue has grown by 37% year-on-year and by 5% since the previous quarter
Growth
What is Agios Pharmaceuticals's growth rate over time
Valuation
What is Agios Pharmaceuticals stock price valuation
P/E
4.71
P/B
1.94
P/S
96.21
EV/EBIT
4.09
EV/EBITDA
4
EV/Sales
90.49
Agios Pharmaceuticals's equity has surged by 146% QoQ and by 83% YoY
The P/B is 29% below the 5-year quarterly average of 2.7 and 17% below the last 4 quarters average of 2.3
AGIO's P/S is 47% above its last 4 quarters average of 64.4
The revenue has grown by 37% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is Agios Pharmaceuticals business performance
Dividends
What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AGIO.
Financial health
How did Agios Pharmaceuticals financials performed over time
The total assets has surged by 132% since the previous quarter and by 78% year-on-year
The total liabilities has increased by 47% since the previous quarter and by 37% year-on-year
The debt is 96% smaller than the equity
Agios Pharmaceuticals's equity has surged by 146% QoQ and by 83% YoY
The debt to equity has shrunk by 60% QoQ and by 56% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.